Ignite Creation Date:
2024-05-05 @ 4:53 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00332163
Status:
COMPLETED
Last Update Posted:
2016-02-23
First Post:
2006-05-31
Brief Title:
Skin Toxicity Treatment in Metastatic Colorectal Cancer mCRC Patients Receiving Panitumumab Irinotecan-based Therapy
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 2 Open-label Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STEPP
Brief Summary:
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer mCRC who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None